Navarro Compán, VictoriaPuig, LuisVidal, SilviaRamírez, JulioLlamas Velasco, MarFernández Carballido, CristinaAlmodóvar, RaquelPinto, José AntonioGalíndez Aguirregoikoa, EvaZarco, PedroJoven, BeatrizGratacós Masmitjà, JordiJuanola, XavierBlanco, RicardoArias Santiago, SalvadorSanz Sanz, JesúsQueiro, RubénCañete, Juan D.2024-03-062024-03-062023-08-041664-3224https://hdl.handle.net/2445/208466Interleukin-17 family (IL-17s) comprises six structurally related members (IL-17A to IL-17F); sequence homology is highest between IL-17A and IL-17F, displaying certain overlapping functions. In general, IL-17A and IL-17F play important roles in chronic inflammation and autoimmunity, controlling bacterial and fungal infections, and signaling mainly through activation of the nuclear factor-kappa B (NF-kappa B) pathway. The role of IL-17A and IL-17F has been established in chronic immune-mediated inflammatory diseases (IMIDs), such as psoriasis (PsO), psoriatic arthritis (PsA), axial spondylarthritis (axSpA), hidradenitis suppurativa (HS), inflammatory bowel disease (IBD), multiple sclerosis (MS), and asthma. CD4(+) helper T cells (Th17) activated by IL-23 are well-studied sources of IL-17A and IL-17F. However, other cellular subtypes can also produce IL-17A and IL-17F, including gamma delta (gamma delta) T cells, alpha beta (alpha beta) T cells, type 3 innate lymphoid cells (ILC3), natural killer T cells (NKT), or mucosal associated invariant T cells (MAIT). Interestingly, the production of IL-17A and IL-17F by innate and innate-like lymphocytes can take place in an IL-23 independent manner in addition to IL-23 classical pathway. This would explain the limitations of the inhibition of IL-23 in the treatment of patients with certain rheumatic immune-mediated conditions such as axSpA. Despite their coincident functions, IL-17A and IL-17F contribute independently to chronic tissue inflammation having somehow non-redundant roles. Although IL-17A has been more widely studied, both IL-17A and IL-17F are overexpressed in PsO, PsA, axSpA and HS. Therefore, dual inhibition of IL-17A and IL-17F could provide better outcomes than IL-23 or IL-17A blockade.14 p.application/pdfengcc by (c) Navarro Compán, Victoria et al., 2023http://creativecommons.org/licenses/by/3.0/es/Malalties cròniquesLimfòcitsPsoriasiChronic DiseaseLymphocytesPsoriasisinfo:eu-repo/semantics/article2023-09-12info:eu-repo/semantics/openAccess37600764